A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
Background: There are no previous reports of paliperidone palmitate’s (PP) long term tolerability or pharmacokinetics of the highest dose in patients with schizophrenia. This study evaluates safety and tolerability, as well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. [234 mg]...
Main Authors: | Coppola, Danielle, Liu, Yanning, Gopal, Srihari, Remmerie, Bart, Samtani, Mahesh N., Hough, David W., Nuamah, Isaac, Sulaiman, Ahmad Hatim, Pandina, Gahan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/9626/1/00000797_78103.pdf |
Similar Items
-
Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
by: Srihari Gopal, et al.
Published: (2017-07-01) -
Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
by: Rui Luo, et al.
Published: (2023-08-01) -
Patient social function and quality of life in schizophrenia: focus on paliperidone palmitate
by: E. V. Grigorieva
Published: (2018-07-01) -
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
by: Ibrahim Turkoz, et al.
Published: (2023-09-01) -
Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia
by: Gihan Elsisi, et al.
Published: (2023-08-01)